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Abstract
Background: The potential benefits of corticosteroids for septic shock may depend on initial mortality risk.
Objective: We determined associations between corticosteroids and outcomes in children with septic shock who were
stratified by initial mortality risk.
Methods: We conducted a retrospective analysis of an ongoing, multi-center pediatric septic shock clinical and biological
database. Using a validated biomarker-based stratification tool (PERSEVERE), 496 subjects were stratified into three initial
mortality risk strata (low, intermediate, and high). Subjects receiving corticosteroids during the initial 7 days of admission
(n = 252) were compared to subjects who did not receive corticosteroids (n = 244). Logistic regression was used to model
the effects of corticosteroids on 28-day mortality and complicated course, defined as death within 28 days or persistence of
two or more organ failures at 7 days.
Results: Subjects who received corticosteroids had greater organ failure burden, higher illness severity, higher mortality,
and a greater requirement for vasoactive medications, compared to subjects who did not receive corticosteroids.
PERSEVERE-based mortality risk did not differ between the two groups. For the entire cohort, corticosteroids were
associated with increased risk of mortality (OR 2.3, 95% CI 1.3–4.0, p = 0.004) and a complicated course (OR 1.7, 95% CI 1.1–
2.5, p = 0.012). Within each PERSEVERE-based stratum, corticosteroid administration was not associated with improved
outcomes. Similarly, corticosteroid administration was not associated with improved outcomes among patients with no
comorbidities, nor in groups of patients stratified by PRISM.
Conclusions: Risk stratified analysis failed to demonstrate any benefit from corticosteroids in this pediatric septic shock
cohort.
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Introduction
The controversy surrounding corticosteroid use in septic shock
has yielded multiple adult randomized controlled trials, yet their
results are conflicting and a consensus has yet to be reached [1–6].
The Surviving Sepsis Campaign guidelines recommend consider-
ing corticosteroid usage in patients with refractory shock, defined
as those who continue to require vasopressors despite adequate
fluid resuscitation [7]. However, physician practices surrounding
adjunctive corticosteroid administration vary significantly [8,9].
Practitioners must weigh the potential hemodynamic improve-
ments seen with corticosteroids against the risks of diminished
wound healing, gastrointestinal bleeding, hyperglycemia, and
immune suppression [4,6,10].
Studies examining corticosteroid use in pediatric septic shock
are less abundant than adult studies, but currently the use of
corticosteroids is recommended for children with fluid-resuscitated
septic shock and evidence of catecholamine resistance or adrenal
insufficiency, although these conditions are not evidence- or
consensus-defined for children [11]. No large randomized
controlled trials examining corticosteroids use in pediatric septic
shock have been completed. However, a meta-analysis of small
trials showed no benefit attributable to corticosteroids [12]. In
addition, two large retrospective observational studies did not
show any survival benefit with corticosteroid use in children with
septic shock [13,14]. One of these studies normalized for illness
severity and organ failure burden, but did not specifically conduct
a risk-stratified analysis [14]. Consequently, the lack of any
survival benefit from corticosteroids may be a reflection of the fact
that those children who received corticosteroids had a higher
initial mortality risk than those who did not receive corticosteroids.
The Surviving Sepsis Campaign guidelines report on an analysis
of ‘‘low risk’’ (placebo mortality rate ,50%) and ‘‘high risk’’
(placebo mortality .60%) patients, demonstrating no benefit in
low risk patients receiving corticosteroids, but a trend toward
lower mortality in high risk patients receiving corticosteroids [15].
A recent retrospective, multicenter, propensity-matched study
stratified patients with septic shock using the Acute Physiology and
Chronic Health Evaluation II (APACHE II) score and reported
that corticosteroids were associated with a survival benefit in
patients occupying the upper quartile of APACHE II scores for
that cohort [16]. Accordingly, the potential benefit of adjunctive
corticosteroids for septic shock would be better understood in the
context of mortality risk stratification.
Recently, a biomarker-based stratification tool was derived and
validated for children with septic shock (Pediatric Sepsis
Biomarker Risk Model, PERSEVERE), allowing for stratification
into mortality risk categories upon pediatric intensive care unit
(PICU) admission [17–21]. A potential application of PERSE-
VERE is to enable stratified analysis of clinical data [22]. We
explored the association between corticosteroids and outcomes in
children with septic shock stratified by risk of mortality. We
hypothesized that, similar to previous reports in adults with septic
shock, any potential benefit of corticosteroids in pediatric septic
shock is dependent on the initial mortality risk as determined by
PERSEVERE. We secondarily hypothesized that the potential
benefit of corticosteroids would also be dependent on illness
severity as determined by the Pediatric Risk of Mortality (PRISM)
score.
Materials and Methods
Ethics statement
All study subjects were enrolled after written informed consent
from parents or legal guardians. The Institutional Review Boards
(IRB) of each participating institution approved secondary use of
biological specimens and clinical data: Cincinnati Children’s
Hospital Medical Center, UCSF Benioff Children’s Hospital
Oakland, Penn State Hershey Children’s Hospital, Children’s
Mercy Hospital, Children’s Hospital of Orange County, Akron
Table 1. Clinical and demographic data for the study subjects.
No Corticosteroids
(n =244)
Corticosteroids
(n =252) P value
Age in years, median (IQR) 2.8 (0.7–7.1) 3.4 (1.3–7.0) 0.097
Males, N (%) 137 (56) 140 (56) 0.966
Deaths, N (%) 21 (9) 43 (17) 0.005
Complicated course, N (%) 53 (22) 80 (32) 0.016
PRISM score, median (IQR) 11 (7–18) 15 (10–22) ,0.001
Mean days to death 6 SD 5.466.8 5.465.7 0.955
Median days to death (IQR) 3 (1–17) 4 (1–12) 0.553
PERSEVERE-based mortality probability, mean
(95% C.I.)
9.8 (7.9–11.7) 12.7 (10.6–14.8) 0.090
Maximum number of organ failures, median (IQR) 2 (1–3) 2 (2–3) 0.025
Gram-positive bacteria, N (%) 60 (25) 58 (23) 0.759
Number of vasoactive agents at the time of
corticosteroid initiation, median (IQR)
– 2 (1–2) –
Maximum number of simultaneous vasoactive agents
during the first 7 days, median (IQR)
1 (1–2) 2 (1–3) ,0.001
Gram-negative bacteria, N (%) 45 (18) 58 (23) 0.252
Other organism, N (%) 19 (8) 25 (10) 0.525
Negative cultures, N (%) 120 (49) 111 (44) 0.291
Comorbidity, N (%) 70 (29) 105 (42) 0.003
doi:10.1371/journal.pone.0112702.t001
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Children’s Hospital, Nationwide Children’s Hospital, Children’s
National Medical Center, Morgan Stanley Children’s Hospital,
Columbia University Medical Center, Miami Children’s Hospital,
Texas Children’s Hospital, CS Mott Children’s Hospital at the
University of Michigan, Children’s Hospital and Clinics of
Minnesota, and The Children’s Hospital of Philadelphia.
Study and Data Collection
The patient cohort (n = 496) was derived from an ongoing
multicenter pediatric septic shock database, which has been
previously described in detail [23–25]. Briefly, children admitted
to the PICU meeting pediatric-specific criteria for septic shock
were eligible for enrollment [26]. After informed consent from
parents or legal guardians, blood samples were obtained as close to
the time of meeting criteria for septic shock as possible (,24
hours). Clinical and laboratory data were collected through the
first seven days of PICU admission. Mortality was tracked for 28
days after enrollment and organ failure was defined using
pediatric-specific criteria [26]. Any neonates (subjects less than
28 days of age) included in the study were full term and admitted
to the PICU with septic shock following discharge to home after
birth. Subjects were enrolled between May 2002 and May 2013.
Patient Classification and Stratification
We surveyed the medication fields of the clinical database to
determine if the study subjects received systemic corticosteroids.
Subjects receiving any formulation of systemic corticosteroids
during the first 7 days of meeting criteria for septic shock were
classified in the corticosteroid group. The one exception was
subjects who received dexamethasone for less than 48 hours for
airway edema. These patients were classified in the no corticoste-
roid group (13 subjects). All other subjects were classified in the no
corticosteroid group. We were unable to consistently determine
dosages or the clinical indications for corticosteroids in all subjects.
The blood sample was used to stratify subjects into mortality risk
strata using PERSEVERE [18,19]. Based on a histogram showing
three main bins, we stratified subjects into low, intermediate, or
high risk categories. The ‘‘low risk’’ population was defined as
those subjects with a mortality probability #2.5%. The ‘‘inter-
mediate risk’’ group was defined as those subjects with a mortality
probability .2.5% up to and including 26.7%. The ‘‘high risk’’
group was defined as subjects with a mortality probability .
26.7%. All subjects in this study were previously included in the
derivation (n= 353) and validation (n= 114) of PERSEVERE.
In a sensitivity analysis, we included only the subjects without
comorbidities as an indirect means of selecting only those subjects
who received corticosteroids for the indication of refractory shock.
In a secondary analysis, subjects were stratified based on the
PRISM score tertiles for this cohort. The first tertile contained
subjects with PRISM scores #10, the second tertile contained
subjects with PRISM scores from 11 through 17, and the third
tertile contain subjects with PRISM scores .17. We selected this
approach to mirror the three PERSEVERE-based risk strata.
Data Analysis
Statistical analyses were conducted using SigmaStat Software
(Systat Software, Inc., San Jose, CA). Initially, data are described
using medians, interquartile ranges, frequencies, and percentages.
Comparisons between study groups used the Mann-Whitney U-
test, Chi-square, or Fisher’s Exact tests, as appropriate.
The association between corticosteroids and outcome was
modeled using logistic regression. First, we modeled the probabil-
ity of all cause 28-day mortality. Second, we modeled the
probability of a composite endpoint termed ‘‘complicated course’’,
which is defined as either death within the 28-day study period, or
persistence of two or more new organ failures at 7 days after
meeting criteria for septic shock, as previously described
[20,22,27]. Complicated course is not a validated endpoint, but
is intended to serve as a pragmatic clinical endpoint that captures
both septic shock-related morbidity and mortality.
Results
Demographics and clinical characteristics
Among the subjects who received corticosteroids, 78% were
prescribed hydrocortisone, 16% were prescribed methylpredniso-
lone, and 6% were prescribed dexamethasone. The median
duration of corticosteroid prescription was 5 days (maximum days
Table 2. Association between corticosteroids and mortality.
Group
# of
deaths
Subjects receiving $2
vasoactive medications # (%) OR 95% C.I. P value
All subjects (n = 496) 64 242 (49) 2.304 1.312–4.046 0.004
Low risk subjects (n = 323) 7 132 (41) 6.898 0.821–57.595 0.075
Intermediate risk subjects (n = 117) 27 66 (56) 1.371 0.563–3.343 0.487
High risk subjects (n = 56) 30 44 (79) 2.333 0.780–6.980 0.130
doi:10.1371/journal.pone.0112702.t002
Table 3. Association between corticosteroids and complicated course (CC).
Group # with CC OR 95% C.I. P value
All subjects (n = 496) 133 1.676 1.119–2.510 0.012
Low risk subjects (n = 323) 37 1.735 0.865–3.482 0.121
Intermediate risk subjects (n = 117) 54 1.000 0.481–2.078 1.000
High risk subjects (n = 56) 42 2.667 0.773–9.194 0.120
doi:10.1371/journal.pone.0112702.t003
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recorded = 7, interquartile range [IQR], 3–7). The median day of
septic shock at which corticosteroids were initially prescribed was
day 1 (IQR, 1–1).
Table 1 describes the demographic and clinical characteristics
of subjects who received corticosteroids (n = 252) and subjects who
did not receive corticosteroids (n = 244). Subjects who received
corticosteroids had higher rates of complicated course and
mortality, a higher median PRISM score, a higher median
number of organ failures, and a greater requirement for vasoactive
medications, when compared to subjects who did not receive
corticosteroids. A greater proportion of subjects who received
corticosteroids had a comorbidity (Table S1). PERSEVERE-based
mortality risk did not differ between the two groups. No other
differences were noted.
Association between corticosteroids and mortality
Table 2 shows the association between corticosteroids and
mortality. In the overall cohort, there were 64 deaths (13%) and
the use of corticosteroids was associated with an increased risk of
death (OR 2.3, 95% CI 1.3–4.0, p = 0.004). Within each risk
stratum, there was no association between the use of corticoste-
roids and mortality.
Association between corticosteroids and complicated
course
Table 3 shows the association between corticosteroids and a
complicated course. Overall, there were 133 (27%) subjects with a
complicated course and the use of corticosteroids was associated
with an increased risk of a complicated course (OR 1.7, 95% CI
1.1–2.5, p= 0.012). When stratified into the three PERSEVERE-
based mortality risk strata, there was no association between the
use of corticosteroids and the risk for a complicated course.
Analysis of subjects without comorbidities
Since we were unable to consistently determine the clinical
indications for corticosteroids in all subjects, we conducted a
sensitivity analysis limiting the dataset to patients without
comorbidities (n = 321). We reasoned that the majority of these
subjects were administered corticosteroids for the indication of
refractory shock.
Table 4. Clinical and demographic data for the study subjects without comorbidities.
No Corticosteroids
(n=174)
Corticosteroids
(n =147) P value
Age in years, median (IQR) 2.4 (0.6–6) 2.2 (1.0–5.5) 0.952
Males, N (%) 92 (52.9) 83 (56.5) 0.595
Deaths, N (%) 14 (8) 27 (18.4) 0.010
Complicated course, N (%) 37 (21.2) 51 (34.7) 0.010
PRISM score, median (IQR) 11 (7–17.3) 16 (11–22) ,0.001
Mean days to death 6 SD 5.967.7 4.764.9 0.540
Median days to death (IQR) 3 (1–6) 3 (2–6) 0.759
PERSEVERE-based mortality probability,
mean (95% C.I.)
11.2% (8.7–13.7) 14.8% (11.7–17.9) 0.191
Maximum number of organ failures, median (IQR) 2 (1–3) 2 (2–3) 0.020
Number of vasoactive agents at the time of
corticosteroid initiation, median (IQR)
– 2 (1–3) –
Maximum number of simultaneous vasoactive
agents during the first 7 days, median (IQR)
1 (1–2) 2 (1–3) ,0.001
Gram-positive bacteria, N (%) 44 (25.3) 36 (24.7) 1.000
Gram-negative bacteria, N (%) 24 (13.8) 29 (19.9) 0.192
Other organism, N (%) 10 (5.7) 16 (11) 0.135
Negative cultures, N (%) 95 (54.6) 66 (45.2) 0.118
doi:10.1371/journal.pone.0112702.t004
Table 5. Association between corticosteroids and mortality in subjects without comorbidities.
Group # of deaths
Subjects
Receiving $2
vasoactive
medications # (%) OR 95% C.I. P value
All subjects (n = 321) 41 162 (50) 2.571 1.293–5.114 0.007
Low risk subjects (n = 202)1 1 85 (42) – – –
Intermediate risk subjects (n = 71) 14 40 (56) 1.707 0.524–5.558 0.375
High risk subjects (n = 48) 26 37 (77) 2.700 0.828–8.807 0.100
1The number of deaths is too small to estimate the odds ratio.
doi:10.1371/journal.pone.0112702.t005
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Among the subjects without comorbidities who received
steroids, 79% were prescribed hydrocortisone, whereas 15% were
prescribed methylprednisolone, and 6% were prescribed dexa-
methasone. The median duration of steroid prescription was 4
days (maximum days recorded = 7, IQR, 3–7). The median day of
septic shock at which corticosteroids were initially prescribed was
day 1 (IQR, 1–1).
Table 4 describes subjects without comorbidities grouped by
whether or not they received corticosteroids. Subjects who
received corticosteroids had higher rates of complicated course
and mortality, higher PRISM scores, higher median number of
organ failures, and a greater requirement for vasoactive medica-
tions, compared to subjects who did not receive corticosteroids.
PERSEVERE-based mortality risk did not differ between the two
groups. No other differences were noted.
Table 5 shows the association between corticosteroids and
mortality in the subjects without comorbidities. There were 41
deaths (13%) and the use of corticosteroids was associated with an
overall increased risk of death (OR 2.6, 95% CI 1.3–5.1,
p = 0.007). Within mortality risk strata, no benefit of corticoste-
roids was observed.
Table 6 shows the associations between corticosteroid use and
complicated course among subjects without comorbidities. Within
this population, there were 88 subjects (27%) with a complicated
course and the use of corticosteroids was associated with an
increased risk of a complicated course (OR 2.0, 95% CI 1.2–3.2,
p = 0.008). When stratified into the three PERSEVERE-based
mortality risk strata, there was no association between corticoste-
roid use and complicated course.
Association between corticosteroids and outcomes using
PRISM-based stratification
Because PRISM scores are more familiar to the critical care
medicine field than PERSEVERE, we conducted a secondary
regression analysis using subjects grouped into low, medium, and
high risk based on PRISM score tertiles. For all subjects, higher
PRISM scores were associated with increased risk of mortality
(OR 1.09, 95% CI 1.07–1.12, p,0.001) and complicated course
(OR 1.08, 95% CI 1.06–1.11, p,0.001). Table 7 shows the
association between corticosteroids and mortality within each
PRISM-based stratum. There was no association between the use
of corticosteroids and mortality within each risk stratum. Similarly,
Table 8 shows the association between corticosteroids and a
complicated course within each risk stratum. There was no
association between the use of corticosteroids and a complicated
course within each risk stratum.
Discussion
We examined the association between corticosteroid adminis-
tration and outcomes in a large, heterogeneous cohort of children
with septic shock from multiple institutions across the United
States. When including all subjects regardless of initial mortality
risk, corticosteroids were associated with poorer outcomes. We
note that subjects who received corticosteroids had greater illness
severity as measured by PRISM score, mortality, organ failure
burden, and requirement for vasoactive medications. Thus, the
finding that corticosteroids were associated with poorer outcomes
in the overall cohort is likely confounded by illness severity.
To account for this important confounder, we stratified the
subjects into three mortality risk strata using PERSEVERE.
Within each mortality risk strata, we observed no benefits
associated with corticosteroid use. These findings are consistent
with previous studies showing no outcome benefit associated with
corticosteroid administration in children with septic shock [12–
14].
Menon et al. conducted a meta-analysis of 447 selected cases
and found no survival benefit associated with corticosteroids in
children with septic shock [12]. Markovitz et al. studied over 6,000
subjects using the Pediatric Health Information System adminis-
trative database and reported that corticosteroids were associated
with increased mortality, although they were not able to account
for illness severity [13]. Zimmerman et al. analyzed the results of
the largest interventional clinical trial in pediatric sepsis and found
that corticosteroids were not associated with improved outcomes
[14]. The subjects in the study by Zimmerman et al. had similar
PRISM scores and organ failure burden in the two treatment
groups, but the study did not explicitly stratify for initial mortality
risk as done here.
Table 6. Association between corticosteroids and complicated course (CC) in subjects without comorbidities.
Group # with CC OR 95% C.I. P value
All subjects (n = 321) 88 1.967 1.196–3.234 0.008
Low risk subjects (n = 202) 21 2.404 0.949–6.090 0.064
Intermediate risk subjects (n = 71) 30 1.013 0.394–2.604 0.978
High risk subjects (n = 48) 37 3.231 0.795–13.123 0.101
doi:10.1371/journal.pone.0112702.t006
Table 7. Association between corticosteroids and mortality based on PRISM tertiles.
PRISM Tertile
# of
deaths
Subjects receiving $2 vasoactive
medications # (%) OR 95% C.I. P value
1st (n = 172) 7 61 (35) 4.048 0.762–21.494 0.101
2nd (n = 169) 13 89 (53) 1.651 0.477–5.710 0.428
3rd (n = 155) 44 92 (59) 1.633 0.781–3.412 0.192
doi:10.1371/journal.pone.0112702.t007
Corticosteroids and Pediatric Septic Shock
PLOS ONE | www.plosone.org 5 November 2014 | Volume 9 | Issue 11 | e112702
An important limitation of this retrospective study is that the
indication for corticosteroids was not standardized across the study
subjects, nor was the general clinical care for sepsis. Corticosteroid
administration was at the discretion of the attending physician,
therefore some corticosteroid administration might have been for
indications other than septic shock. We note, however, that 78%
of the overall cohort was prescribed hydrocortisone and the
median day of hydrocortisone administration was ‘‘day 1’’ of
meeting criteria for septic shock. In addition, subjects who
received corticosteroids had a greater requirement for vasoactive
medications. These observations are consistent with the Surviving
Sepsis Campaign recommendations for adjunctive corticosteroid
administration in patients with septic shock. To further account for
this confounder, we conducted a sensitivity analysis that excluded
subjects with comorbidities. By limiting subjects to those without
comorbidities, we hoped to exclude subjects who received
corticosteroids for chronic diseases and indications other than
septic shock. Similar to the overall cohort, the subjects who
received corticosteroids in this cohort with no comorbidity had
greater illness severity and the use of corticosteroids was associated
with worse outcomes overall. When this cohort with no
comorbidity was stratified by initial mortality risk using PERSE-
VERE, there was no benefit associated with corticosteroid use in
any risk stratum. The same pattern was observed using the more
familiar PRISM score to stratify patients: we found no survival
benefit associated with the use of corticosteroids in any PRISM-
based risk stratum.
The timing of corticosteroids was not standardized for patients
included in this analysis. This may be important because a recent,
small study suggests that administration of corticosteroids within
nine hours of vasopressor initiation leads to improved outcomes
[28]. Conversely, a much larger study by Casserly et al. showed
that adjunctive corticosteroids are associated with increased
adjusted hospital mortality even when prescribed within eight
hours of vasopressor initiation [3]. It is unclear, then, how variable
timing of corticosteroids might have influenced our findings.
Another limitation of our study is that we could not determine
whether patients were diagnosed with relative adrenal insufficien-
cy. It has been suggested that patients with relative adrenal
insufficiency may benefit the most from corticosteroid adminis-
tration [1]. While relative adrenal insufficiency has been shown to
exist in critically ill children depending on the definition used,
there is little data on the association between corticosteroids and
pediatric outcomes in the context of relative adrenal insufficiency
[29]. Therefore, relative adrenal insufficiency may remain a
confounder in our study and should be incorporated in future
studies. Finally, the retrospective design of our study makes it
impossible to determine whether associations between corticoste-
roid use and poorer outcomes in the overall cohort are causal or
simply associated with initial mortality risk. To explore this
relationship further, a randomized controlled trial using mortality
risk-stratification at study entry is warranted.
In conclusion, risk stratified analysis failed to demonstrate any
benefit from corticosteroids in this pediatric septic shock cohort.
Thus, apart from children receiving chronic steroids and children
with ‘‘classic’’ adrenal insufficiency, the accumulating evidence
does not support the routine use of corticosteroids in children with
septic shock in the absence of a randomized trial.
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